Univercells launches new CDMO for cell and gene therapy sector

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

The company’s new CDMO, Exothera, has been created to help the cell and gene therapy sector increase its capacity, and also boost its bioprocessing expertise. The CDMO will create bespoke bioproduction support programmes for manufacturers to achieve successful market entry through a combination of bioprocessing experience and best-in-class technologies.

Univercells’ manufacturing platforms will be utilised to achieve cost-effective viral vector processes with the option of implementing commercial facilities at the customer site if desired. The CDMO aims to use a holistic approach to rapidly deliver scalable bioproduction processes and help get new therapies to market faster and with reduced costs.

Exothera will be based at the company’s Jumet site in Belgium, which will be revamped to accommodate new facilities, including laboratories, cleanrooms, and GMP qualified manufacturing areas for clinical and commercial production.

The flexible GMP areas at Jumet will contain Exothera’s CDMO activities and ongoing Univercells vaccine development and manufacturing initiatives, with capacity for rapid response programmes. On the rapid response front, the company is currently pursuing support opportunities for Covid-19 vaccine innovators, drawing on vast capability and know-how in expediting successful vaccine manufacturing programmes.

“This new focus will enable our team to leverage expertise with innovation to overcome the industry’s production constraints and foster the success of cell and gene therapies”, declares Hugues Bultot, CEO of Univercells and Exothera.“We strongly believe that Exothera will make a difference in the manufacturing of these advanced and critically needed therapies, ultimately unlocking their potential to improve patients’ lives.”

Latest stories

Related stories

Why Custom Tin Containers Are Reshaping Medicine & Supplement Packaging

In an industry driven by both compliance and consumer...

Sarclisa by Sanofi has EC Approval to Treat Multiple Myeloma

In order to treat multiple myeloma in adults, Sarclisa...

US Levies 15% Tariff on EU for Pharmaceutical Products

The European Union is going to pay the US...

EU-US Trade Deal Taking Shape as Pharma Tariffs Materialize

Finally, the Trump administration’s much-animated tariffs on pharmaceutical imports...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back